Genetron Holdings Ltd (GTH) Stock
GTH is no longer traded. Genetron Holdings was delisted from the Nasdaq in March 2024.
Prices on this page are historical; the last trade was March 28, 2024 at $4.03.
Genetron Holdings stock price history
GTH final trading statistics
- Final close
- $4.03
- Final trading day
- Mar 28, 2024
- Market cap at delisting
- $127.29M
- Shares outstanding
- 31.62M
- Final 52-week range
- $0.69 – $4.05
- Avg. volume (final 3 mo.)
- 51,071
- All-time high (split-adj.)
- $91.92 · Feb 2021
- All-time low (split-adj.)
- $2.29 · Sep 2022
- Return since IPO
- -91.6%
- Beta
- 0.50
- Book value / share
- $17.90
- Price / book
- 0.22
Genetron Holdings annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $650.71M | -$883.9M | — |
| FY2021 | $531.95M | -$438.4M | -$0.52 |
| FY2020 | $424.49M | -$198.1M | -$0.49 |
| FY2019 | $323.43M | -$321.5M | — |
| FY2018 | $225.18M | -$465.0M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Genetron Holdings Ltd
Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.
Genetron Holdings stock FAQ
What happened to Genetron Holdings stock?
Genetron Holdings stock was delisted from the Nasdaq. Its final close was $4.03 on March 28, 2024.
Is GTH stock still trading?
No. GTH was delisted from the Nasdaq in March 2024 and no longer trades on a U.S. exchange.
What was the last price of GTH stock?
GTH closed at $4.03 on its final trading day, March 28, 2024, for a market value of about $127.29M.
What were Genetron Holdings's revenue and earnings in its last full fiscal year?
Genetron Holdings reported revenue of $650.71M and net income of -$883.9M in fiscal 2022, its last full year as a public company.
When did Genetron Holdings go public?
Genetron Holdings Ltd stock began trading on June 15, 2020.